Pompe Disease Therapeutic Market Excellent Growth 2021 Top Key Players
Pompe disease or also referred to as Glycogen storage disease type II is an autosomal recessive metabolic disorder that damages nerve cells and muscles through the entire body.
Rising
prevalence of Pompe disease is expected to operate a vehicle growth
of the global Pompe
Disease Therapeutic Market
throughout the forecast period. Based on the National Organization
for Rare Disorders (NORD), around 1 in 40,000 births in the U.S. and
the Netherlands are affected with Pompe disease. Based on the same
source, a current study revealed that their state of Missouri
reported a greater prevalence of 1 in 5,463. Pompe disease can occur
in a variety of populations and ethnic groups across the globe.
Among regions, North America is anticipated to witness significant growth in the global Pompe disease therapeutic market throughout the forecast period. This really is owing to the presence of robust healthcare infrastructure across the region. Furthermore, Europe is expected to register a powerful growth rate on the forecast period, owing to continuous research and development activities along with proactive support from government authorities to boost the healthcare sector.
Key companies operating in the global Pompe Disease Therapeutic Market are CENTOGENE AG, Amicus Therapeutics, Inc., AVROBIO, Inc., Sanofi, Valerion Therapeutics, Audentes Therapeutics, and Oxyrane.
Comments
Post a Comment